Sentences with phrase «on cancer patients in»

Not exact matches

• Quentis Therapeutics, a New York City - based biotech company that focuses on treating cancer patients, raised $ 48 million in Series A funding.

In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared with those given a placebo.

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

So, along with Memorial Sloan Kettering, Grail plans on following hundreds of thousands of patients over the next few years and trying to see if they can detect CTDNA in those patients whenever they develop cancer.

Basically, CAR - T therapy involves taking a patient's own immune «killer» T - cells, inserting new genetic code into those cells which turn them into cancer - hunters that can home in on malignant B - cells (another kind of immune cell), and then pumping these specialized leukemia - busting cells back into the patient.

The first step in the process is to surgically remove the patient's tumor and ensure that the patient is cancer free by confirming that there is no sign of cancer on blood tests and imaging studies.

If they can figure out what's going on and how to prevent the neurological side effects for cancer patients, the same approach could hold some promise in treating Alzheimer's as well.

The medicines, which help unleash the immune system on cancer cells, were tested in patients with advanced lung cancer.

The study, just published in Science, showed that the creation of what the researchers are calling microtumors can help predict drug effectiveness in cancer patients better than the current standard method of testing the drugs on rodents.

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

Other studies, meanwhile, are examining tryp's potential efficacy as an antifungal agent; and as a prognostic indicator in patients with brain cancer (as seen by increased uptake of the amino acid on a PET scan).

«The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers,» Celgene CEO Mark Alles said in a statement Monday.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

In 2000, Medarex began its first phase of human testing on its new «CTLA -4-blockade» — in patients who had either prostate cancer or metastatic melanoma, a deadly form of skin canceIn 2000, Medarex began its first phase of human testing on its new «CTLA -4-blockade» — in patients who had either prostate cancer or metastatic melanoma, a deadly form of skin cancein patients who had either prostate cancer or metastatic melanoma, a deadly form of skin cancer.

This new kind of approach to fighting blood cancers is truly personalized; immune T - cells are extracted from patients, genetically tinkered to home in on an destroy cancerous cells, multiplied in a lab, and then jolted back into the patient's body within about two weeks.

Sierra Oncology, Inc., a clinical stage drug development company focused on advancing next - generation DNA damage response therapeutics for the treatment of patients with cancer, went public near $ 29 in July 2015, then began a downtrend that continued through a June 2017 all - time low of $ 1.10.

'' «At PMV Pharmaceuticals, we are targeting the most frequently mutated gene in human cancer (p53) to make an unprecedented impact on cancer patients» lives.

A glut of liquid biopsy companies have emerged from universities and elsewhere in recent years to catch cancer by relying on a patient's DNA, rather than having to extract their tissue.

I've owned it for the past three years with a cost average of $ 4.64 - it's the future of cancer treatment in my opinion, with brain cancer patients living 7 plus years on its lead drug and impressive results in its second drug candidate for triple negative breast cancer.

Shkreli, who was arrested Thursday morning on securities fraud charges, has effectively waved a red flag for months in front of federal prosecutors, keeping himself in the media glare with a hugely controversial price hike of a drug that benefits AIDS patients, pregnant women and cancer patients, attacking his critics, including presidential contender Hillary Clinton, and lighting up Twitter with outrageous statements.

«But it also increasingly looks destined to disappoint patients — the latest in a long trail of failed quests to win the war on cancer.»

This surgeon was one of the best in this field and had even successfully tried a treatment on this exact cancer for other patients that tripled the five - year - survival odds — from 5 percent to 15 percent — albeit with a poor quality of life.

In research in patients with cancer, with a focus on psycho - emotional symptoms, and with some attempt at measuring spirituality, patients respond to the diagnosis and management of cancer more as whole persons, and they rely on faith, reason, and emotioIn research in patients with cancer, with a focus on psycho - emotional symptoms, and with some attempt at measuring spirituality, patients respond to the diagnosis and management of cancer more as whole persons, and they rely on faith, reason, and emotioin patients with cancer, with a focus on psycho - emotional symptoms, and with some attempt at measuring spirituality, patients respond to the diagnosis and management of cancer more as whole persons, and they rely on faith, reason, and emotion.

In a chapter on «Stigma» Frank notes that no one called his heart attack «h.a.,» but many took refuge in cancer as «c.a.» The patient responds by seeking to be invisiblIn a chapter on «Stigma» Frank notes that no one called his heart attack «h.a.,» but many took refuge in cancer as «c.a.» The patient responds by seeking to be invisiblin cancer as «c.a.» The patient responds by seeking to be invisible.

But he approves of it in the case of a physician who» knowingly facilitated» the suicide of a patient whom he had treated for a long time, knew well, and who had convinced him early on that she preferred to die rather than go through a long and losing battle with cancer.

One - vignette: a dying cancer patient, a man in his forties, demanded to be placed on his feet (he was in great pain) and was obeyed because of his moral authority.

That the issue at stake is a spiritual one is evident in the religious imagery that pervades Callahan's account of technological medicine: that the war on death is a search for «immortality»; that the dying patient might be «saved»; that medicine is seen as «omnipotent, holding life and death wholly in its hands»; that a lobbyist equates heart attacks, cancer, and strokes with sin (interesting rhetoric in the public sphere, but I'll save that discussion for another day).

There is a general need for more understanding, comfort and expertise on the part of the clergy in their ministry to patients with cancer and to their families.

A randomized, blinded study of the impact of intercessory prayer on spiritual well - being in patients with cancer.

In an article posted on MD Anderson's blog, professor in the Department of Experimental Therapeutics, Dr. Bharat Aggarwal, Ph.D., points out that, «Symptoms common in cancer patients, such as depression, fatigue, neuropathic pain, metastases and tumor growth, are due to inflammatioIn an article posted on MD Anderson's blog, professor in the Department of Experimental Therapeutics, Dr. Bharat Aggarwal, Ph.D., points out that, «Symptoms common in cancer patients, such as depression, fatigue, neuropathic pain, metastases and tumor growth, are due to inflammatioin the Department of Experimental Therapeutics, Dr. Bharat Aggarwal, Ph.D., points out that, «Symptoms common in cancer patients, such as depression, fatigue, neuropathic pain, metastases and tumor growth, are due to inflammatioin cancer patients, such as depression, fatigue, neuropathic pain, metastases and tumor growth, are due to inflammation.

So in 2014, we embarked on this endeavor with Hormel Health Labs (HHL) to improve cancer patients» quality of life.»

While other measures lacked the same urgency or drama as mayoral control, which did not get done this session, lawmakers did approve scores of bills in recent days, like a provision that would make it easier for cancer patients to sue for malpractice, and a ban on e-cigarettes in bars and restaurants.

But Taub, who said he believed he «was put on Earth to help» mesothelioma patients suffering from what was described repeatedly as a horrible disease, said he held Weitz & Luxenberg in low esteem because of the firm's reluctance to donate portions of its often highly lucrative cancer settlements to medical research.

In a post on her Facebook page, Sandra Lee thanked her fans and fellow breast cancer patients for sharing their personal experiences with recovery.

Silver asked Taub to refer cancer patients through him to Weitz & Luxenberg, where court papers say Silver got a 33 percent cut of the firm's earnings on any asbestos cases he brought in.

An expert in Radiotheraphy and Oncology, Prof. Aderemi Tajudeen Ajekigbe, has raised an alarm on the prevalence of cancer disease in the country, saying there were about two million cancer patients in Nigeria.

Speaking on the 31st Convocation lecture of the institution titled» Stepping Out Into The World; Potential Well - Being, Change in Lifestyle And Cancer Education», the don lamented the drain the disease cost on the nation's resources through just about five per cent of the cancer patients (10,000) that had resources to go abroad where they pay between $ 10,000 - $ 15,000 per patient for a three to five weeks course of RadiothCancer Education», the don lamented the drain the disease cost on the nation's resources through just about five per cent of the cancer patients (10,000) that had resources to go abroad where they pay between $ 10,000 - $ 15,000 per patient for a three to five weeks course of Radiothcancer patients (10,000) that had resources to go abroad where they pay between $ 10,000 - $ 15,000 per patient for a three to five weeks course of Radiotherapy.

Tessa Jowell receives a standing ovation in the House of Lords, after she delivers moving speech on cancer care, appealing for patients to be able to trial treatments https://t.co/krOn1sstn2 pic.twitter.com/Fa 1bOJgKDi

Ahead of the general election Macmillan will be calling on all three parties to commit to: • deliver cancer outcomes that match the best in Europe • ensure all cancer patients are treated with the highest levels of dignity and respect and that staff are supported to do this • ensure everyone at the end of life is given free social care to support them to spend their final weeks and days in the place of their choosing.

Statement from Breast Cancer Care on research from the Queen's Medical Centre, Nottingham, presented to the seventh European Breast Cancer Conference on the use of beta - blockers to help reduce metastasis and improve survival in breast cancer patCancer Care on research from the Queen's Medical Centre, Nottingham, presented to the seventh European Breast Cancer Conference on the use of beta - blockers to help reduce metastasis and improve survival in breast cancer patCancer Conference on the use of beta - blockers to help reduce metastasis and improve survival in breast cancer patcancer patients.

Challenges highlighted for the year ahead were: Moving forward on piloting flexible sigmoidoscopy bowel screening; a national awareness campaign on bowel cancer; improving diagnostic capacity and productivity; the needs of survivors in different post-treatment phases; providing information to commissioners and providers about patients» experience of care; giving support to tackle issues such as information provision and better communication.

On 14 April 1999, Marsden introduced the Cancer Care Bill [6] with backing from cancer charities including Macmillan Cancer Support, under the Ten Minute Rule that would create the first comprehensive directory of cancer services in the UK to aid patients in identifying the location and type of cancer care avaiCancer Care Bill [6] with backing from cancer charities including Macmillan Cancer Support, under the Ten Minute Rule that would create the first comprehensive directory of cancer services in the UK to aid patients in identifying the location and type of cancer care avaicancer charities including Macmillan Cancer Support, under the Ten Minute Rule that would create the first comprehensive directory of cancer services in the UK to aid patients in identifying the location and type of cancer care avaiCancer Support, under the Ten Minute Rule that would create the first comprehensive directory of cancer services in the UK to aid patients in identifying the location and type of cancer care avaicancer services in the UK to aid patients in identifying the location and type of cancer care avaicancer care available.

In 2003, Dr. Taub noticed Mr. Silver's name on the letterhead of Weitz & Luxenberg, a law firm that represents patients with mesothelioma, the type of cancer he treats.

As a result, waiting times are higher in Wales, cancer patients are being denied life - prolonging drugs which they would have access to if they lived in England, and spending on medicines has «decreased at a faster rate than elsewhere in the UK», according to the Office for Health Economics.

Manhattan - based Weitz & Luxenberg paid Silver more than $ 3 million in referral fees from legal settlements and verdicts won on behalf of patients suffering from mesothelioma, a cancer caused by exposure to asbestos.

During this in depth study, an international team of researchers led by British scientists investigated the impact of anti-hormone therapy on samples taken from patients with prostate cancer.

I'll give real life examples of nocebo, from the man who almost put himself in a coma after «overdosing» on placebo anti-depressants, to the patient mis - diagnosed with liver cancer who died tumour - free within the three months he was told he had left to live.

Associate professor Mary - Ellen Taplin, of the Dana - Farber Cancer Institute, Boston, USA, will tell the 26th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, that galeterone was well tolerated by patients in the ARMOR2 trial, and also lowered PSA levels in a subset of men with CRPC that was resistant to other drugs that target the cancer, such as enzalutamide and abiratCancer Institute, Boston, USA, will tell the 26th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, that galeterone was well tolerated by patients in the ARMOR2 trial, and also lowered PSA levels in a subset of men with CRPC that was resistant to other drugs that target the cancer, such as enzalutamide and abiratCancer Therapeutics in Barcelona, Spain, that galeterone was well tolerated by patients in the ARMOR2 trial, and also lowered PSA levels in a subset of men with CRPC that was resistant to other drugs that target the cancer, such as enzalutamide and abiratcancer, such as enzalutamide and abiraterone.

In his call for practice change, Bekelman cites research showing the shorter radiation treatment — known as moderate hypofractionation — is just as effective at treating cancer, while costing less and easing the burden on patients.

Many researchers have conducted literature reviews on the impact of religion and spirituality on cancer patients» health, but none have taken such thorough and painstaking efforts to analyze the data in such detail.